PHARMACOLOGY 1: • INHIBIT B CELL

• MOA: interact against the CD20 antigen found on
the surface of normal and malignant B
lymphocytes, resulting in B CELL DEPLETION

(GIVEN IV EVERY 16 TO 24 WEEKS; METHYLPREDNISOLONE is administered 30 mins prior to infusion to reduce severity of infusion reactions)

Question

• INHIBIT B CELL

• MOA: interact against the CD20 antigen found on 
the surface of normal and malignant B 
lymphocytes, resulting in B CELL DEPLETION

(GIVEN IV EVERY 16 TO 24 WEEKS; METHYLPREDNISOLONE is administered 30 mins prior to infusion to reduce severity of infusion reactions)

LEIGHTON DWIGHT OBILLOS · Accepted Answer

RITUXIMAB

• INHIBIT B CELL • MOA: interact against the CD20 antigen found on the surface of normal and malignant B lymphocytes, resulting in B CELL DEPLETION (GIVEN IV EVERY 16 TO 24 WEEKS; METHYLPREDNISOLONE is administered 30 mins prior to infusion to reduce severity of infusion reactions)